28/03/2026
📰 What happens when real-world need moves faster than scientific evidence?
A landmark Lancet Psychiatry review has been widely shared, and widely misread.
It doesn’t say cannabinoids “don’t work” for mental-health symptoms.
It says the clinical trials we rely on are too small, too limited, and too disconnected from real-world patient use to give us meaningful certainty.
And that gap matters.
Because outside of controlled trials, the reality looks very different.
Since COVID, the UK has experienced a sharp rise in mental-health challenges and many haven’t found effective relief through conventional pathways. At the same time, more people are turning to alternative options when the system isn’t meeting their needs.
We see this firsthand: 53% of Mamedica patients are now prescribed medical cannabis for mental-health conditions, and referrals for depression, anxiety, PTSD and neurodivergent conditions are up 42% since 2024.
🚨 This isn’t a trend, it’s a signal.
A reflection of unmet need, inadequate access, and people adapting in the only ways they can.
The Lancet review doesn’t close the door on cannabinoids for mental health.
If anything, it shows us what’s missing:
👉🏼 research that reflects the scale of the problem, the complexity of patients’ lives, and the treatments they’re already using.
Until then, headlines will keep oversimplifying a story that deserves far more nuance.
The evidence must catch up, to the need, to the reality, and to the patients themselves. What are your thoughts? 💭👇🏼
